Trial · NCT02809183
Results by group64
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 64
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | Pooled Placebo | Subjects Reporting any TEAE | 14 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 1.5g TRC101 BID | Subjects Reporting any TEAE | 13 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 3g TRC101 BID | Subjects Reporting any TEAE | 9 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 4.5g TRC101 BID | Subjects Reporting any TEAE | 17 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 6g TRC101 QD | Subjects Reporting any TEAE | 17 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | Pooled Placebo | ≥ 1 Mild TEAE | 11 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 1.5g TRC101 BID | ≥ 1 Mild TEAE | 9 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 3g TRC101 BID | ≥ 1 Mild TEAE | 8 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 4.5g TRC101 BID | ≥ 1 Mild TEAE | 14 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 6g TRC101 QD | ≥ 1 Mild TEAE | 15 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | Pooled Placebo | ≥ 1 Moderate TEAE | 3 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 1.5g TRC101 BID | ≥ 1 Moderate TEAE | 4 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 3g TRC101 BID | ≥ 1 Moderate TEAE | 1 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 4.5g TRC101 BID | ≥ 1 Moderate TEAE | 3 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 6g TRC101 QD | ≥ 1 Moderate TEAE | 2 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | Pooled Placebo | ≥ 1 Severe TEAE | 0 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 1.5g TRC101 BID | ≥ 1 Severe TEAE | 0 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 3g TRC101 BID | ≥ 1 Severe TEAE | 0 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 4.5g TRC101 BID | ≥ 1 Severe TEAE | 0 | Participants | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE | 6g TRC101 QD | ≥ 1 Severe TEAE | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02809183/results